Abstract
Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease of the esophagus. It is diagnosed in the setting of symptoms of esophageal dysfunction and an eosinophilic predominant infiltrate in the esophagus. The condition is rapidly increasing in incidence and prevalence and is commonly encountered in gastroenterology and allergy practices, emergency departments, and primary care settings. Over the past decade, there have been paradigm shifts in disease diagnosis and management, increases in knowledge about EoE risk factors, natural history, and pathogenesis, and development of validated outcome metrics. This updated American College of Gastroenterology Clinical Guideline uses Grading of Recommendations, Assessment, Development, and Evaluation methodology to make recommendations across domains of diagnosis, treatment, monitoring and assessment of response, and pediatric-specific considerations. Proton pump inhibitors, topical steroids, empiric diet elimination, a biologic, and esophageal dilation are all recommended treatments; feeding therapy is used adjunctively in children with food aversion or feeding dysfunction. Monitoring with clinical, endoscopic, and histologic assessments is recommended to assess for treatment response and follow patients over time with maintenance therapy. When evaluating and following patients with EoE, consideration should be given to assessing and controlling both the inflammatory and fibrostenotic aspects of disease.
Original language | English (US) |
---|---|
Pages (from-to) | 31-59 |
Number of pages | 29 |
Journal | American Journal of Gastroenterology |
Volume | 120 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2025 |
Funding
Potential competing interests: E.S.D.: research funding: Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, and Shire/Takeda; consultant: Abbott, AbbVie, Adare/Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Knightpoint, Landos, LucidDx, Morphic, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE, and Upstream Bio; educational grant: Allakos, Aqilion, Holoclara, and Invea. A.B.M.: medical advisory board: Takeda, Bristol Meyer Squib, and Regeneron/Sanofi; Nexstone Immunology; research funding: Allakos. D.A.K.: research with Medtronic and speaking honorarium from Regeneron. S.C.S.: consultant for Phathom Pharmaceuticals and RedHill Biopharma. B.G.S.: consultant for Regeneron, Sanofi, and Takeda. S.S.A.: research funding from Bristol Meyer Squibb, consultant\u2014Sanofi, Disease State Awareness; speaker\u2014Regeneron, Sanofi, royalties through UCSD patent and Takeda license of budesonide oral suspension (Eohilia). G.T.F.: chief medical officer\u2014EnteroTrack; consultant\u2014Takeda, Bristol Meyer Squibb, and Phathom Pharmaceuticals. Research support\u2014Pfizer/Arena. N.G.: consultant for Allakos, AstraZeneca, Bristol Myers Squibb, Regeneron/Sanofi, and Takeda; speaker fees from Sanofi and Regeneron. I.H.: consultant for AbbVie, Ellodi/Adare, Allakos, Pfizer/Arena, AstraZeneca, Celgene/Receptos/Bristol Myers Squibb, Dermavant, Esocap, Eupraxia, Nextsone, Parexel/Calyx, Phathom, Regeneron/Sanofi, Shire/Takeda, and Phathom Pharmaceuticals. Grant/research support from Pfizer/Arena, Celldex, Ellodi/Adare, Allakos, AstraZeneca, Celgene/Receptos/Bristol Myers Squibb, Sanofi/Regeneron, and Shire/Takeda. Speaker fees from Sanofi and Regeneron.
Keywords
- biologics
- diet elimination
- dilation
- eosinophilic esophagitis
- eosinophilic oesophagitis
- maintenance thearpy
- monitoring
- pediatrics
- proton pump inhibitors
- topical steroids
- treatment
ASJC Scopus subject areas
- Hepatology
- Gastroenterology